PSYCHIATRY ALERTS CHILD& ADOLESCENT. ADHD Medication Abuse. Predictors of Adolescent Suicide
|
|
- Kerry Gibson
- 6 years ago
- Views:
Transcription
1 ADHD Medication Abuse...49 CHILD& ADOLESCENT PSYCHIATRY ALERTS CBT for Suicide Prevention...50 CYP Genotypes and Treatment Outcome...52 Evidence-Based Psychopharmacology...53 Long-Term Depression Treatment...51 Pediatricians Treating ADHD...53 Suicide Predictors...49 Volume XI / September 2009 / Number 9 ADHD Medication Abuse A review of national poison control center data shows that prescription of medications for ADHD has risen in recent years and that along with the increase came a rise in the abuse/ misuse of the agents. The National Poison Data System was queried to identify all calls received between 1998 and 2005 that involved intentional abuse/misuse of methylphenidate or amphetamine/ dextroamphetamine by adolescents aged years. The total number of prescriptions for these medications was estimated based on physician surveys and manufacturer sales data. The annual number of prescriptions written for stimulant medications increased 80% over the study years. Prescriptions for ADHD-related amphetamine/dextroamphetamine rose 133%, but the number of calls received that pertained to misuse/abuse of these medications increased by 476%: from 71 in 1998 to 409 in In contrast, methylphenidate prescriptions for ADHD rose 52%, but related calls decreased by 30%. Setlik J, Bond R, Ho M: Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. Published online August 24, 2009 at doi /peds From the University of Cincinnati, Ohio. Funded by the Rocky Mountain Poison and Drug Center, a nonprofit government agency. The authors disclosed no potential conflicts of interest. Drug Trade Names: amphetamine/dextroamphetamine Adderall; methylphenidate Ritalin Predictors of Adolescent Suicide The multifaceted NIMH-funded Treatment of Adolescent Suicide Attempters Study (TASA) was designed to address the pressing need for effective suicide prevention strategies for adolescents. Patients: TASA included 124 adolescents (aged years) with a major unipolar mood disorder who had attempted suicide in the 90 days before study entry and were currently experiencing at least moderate depressive symptoms. Substance abuse, psychosis, developmental disorders, and bipolar disorder were exclusion criteria. Assessments: Baseline evaluations collected information on the lethality and intent of the index and previous suicide attempts as well as the number of previous attempts. Patients underwent CHILD & ADOLESCENT PSYCHIATRY ALERTS (ISSN ) is published monthly by M.J. Powers & Co. Publishers, 65 Madison Ave., Morristown, NJ Telephone child@alertpubs.com. Periodical-class postage paid at Morristown, NJ, and at additional mailing offices. POSTMASTER: Send address changes to Child & Adolescent Psychiatry Alerts, 65 Madison Ave., Morristown, NJ by M.J. Powers & Co. Publishers. Written permission from M.J. Powers & Co. is required to reproduce material from this publication. Subscription $89 a year in the U.S.; $97.50 Canada; $ elsewhere; $141 institutional. Back issues and single copies are available for $10.00 each, prepaid. Subscribers may enroll in the 12-month CME program for $77.00 per year. 49
2 structured diagnostic interviews and validated symptom ratings scales were administered. In the intent-to-treat analysis, the primary outcomes of interest were suicidal events including attempted or completed suicide, preparatory actions, suicidal behavior and/or ideation. A series of logistic regression analyses were used to identify potential predictors of suicidal events. Interventions: Initially the study was intended as a randomized controlled trial comparing a newly designed CBT program, a medication algorithm, and combination treatment. However, because of slow recruitment, patients were allowed to choose between randomization and selecting their own treatment. After creating a safety plan, patients received study treatment for 6 months. The CBT program is described in a separate article in this issue (see next story) and the medication algorithm will be covered in a future Child & Adolescent Psychiatry Alerts issue. Results: A total of 24 patients experienced a suicidal event during the 6 month study; risks were similar for less serious events and repeat attempts. The mean time to the event was <7 weeks, which may suggest therapies had not yet reached an adequate "dose." Strong clinical predictors of suicidal events included high levels of baseline suicidal ideation and self-reported depression, a history of physical or sexual maltreatment, having 2 previous attempts, lower lethality of the index episode, and poorer family cohesion. Discussion: Although the study design does not allow for efficacy comparisons between the treatment groups, factors predictive of suicidal events were identified. The authors suggest a randomized controlled trial of treatments targeting these factors. Brent D, Greenhill L, Compton S, Emslie G, et al: The treatment of adolescent suicide attempters study (TASA): predictors of suicidal events in an open treatment trial. Journal of the American Academy of Child and Adolescent Psychiatry. Published online August 26, 2009 at doi /CHI.0b013e3181b5dbe4. From the NIMH; and other institutions. Funded by the NIMH. Several study authors have disclosed commercial relationships that might pose conflicts of interest. CBT for Suicide Prevention The cognitive behavioral therapy for suicide prevention (CBT-SP) program used in the TASA study (see previous article) consists of newly developed treatment modules, some mandatory and others optional, designed to reduce risk factors, enhance coping strategies, and prevent suicide. A core feature of CBT-SP is its individualized nature, wherein physicians, patients, and family members collaborate to decide which modules would be most beneficial. The present report details the feasibility and acceptability of the program. Of the 124 TASA participants (aged years), 110 participated in the CBT-SP program. These adolescents had relatively severe depression (baseline Children s Depression Rating Scale score, 51) and an average of 2.3 previous suicide attempts. The initial CBT-SP phase includes a chain of events analysis of the index suicide episode; creation of a stepwise safety plan that includes both internal and external strategies; psychoeducation about suicide and the role of underlying depression; a discussion of reasons to live and the creation of a "hope kit" with reminders of those reasons. Clinicians then develop an individualized case conceptualization for each patient and prioritized the skills training needed to prevent a future attempt. After the immediate crisis resolves, the optional individual and family behavioral and training modules are chosen based on patient needs tempered by the recognition of a limited time frame. Individual modules include behavioral activation; increasing pleasurable activity; mood monitoring; emotion regulation and distress tolerance techniques; cognitive restructuring; problem solving; goal setting; and assertiveness training. Family modules include behavioral activation, emotion regulation, problem solving, communication, and cognitive restructuring. The final component is a relapse prevention task during which the 50 C&A PSYCHIATRY ALERTS / September 2009
3 patient remembers the index episode and then applies the newly learned behavior to imagine a changed outcome. The CBT-SP appeared to be both feasible to use and acceptable to study participants. In spite of the difficult nature of the study population adolescents and suicidal patients are difficult to retain in treatment nearly three-fourths of patients completed at least the first phase of the CBT-SP. All patients who completed an exit interview reported that the treatment was helpful. Efficacy in suicide prevention was not addressed in this report and according to the authors should be evaluated in a controlled trial. Stanley B, Brown G, Brent D, Wells K, et al: Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. Journal of the American Academy of Child and Adolescent Psychiatry. Published online August 26, 2009 at doi /CHI.0b013e3181b5dbfe. From Columbia University, New York, N.Y.; and other institutions. Funded by the NIMH. Several study authors have disclosed commercial relationships that might pose conflicts of interest. TADS Follow-Up The 4-stage multicenter randomized controlled TADS (Treatment for Adolescents with Depression Study) evaluated cognitive behavioral therapy, fluoxetine (Prozac) monotherapy, and combined treatment in adolescents with moderate-to-severe depression. In stage 4, long-term treatment was found to be associated with persistent improvement 1 year after study treatments were withdrawn. 1 Stage I. Adolescents with depression received 12 weeks of randomized treatment with flexibledose fluoxetine, CBT, combined treatment, or placebo. 2 Combined treatment was found to be the most effective option in terms of reduced depressive symptoms and suicidality. Response rates at 12 weeks were 71% with combined treatment, 61% with fluoxetine monotherapy, and 43% with CBT monotherapy. Stages II and III. Patients with partial response to initial treatment received unblinded continuation for an additional 24 weeks. Outcome evaluations were completed after a total of 18 and 36 weeks of treatment. At 18 weeks combination therapy remained superior to the other treatments with a response rate of 85%, compared with 69% with fluoxetine and 65% with CBT. 3 However, between 18 and 36 weeks, response rates converged and at the end of treatment there were no significant differences between the groups (86% for combined therapy and 81% for both fluoxetine and CBT monotherapy). Suicidal ideation was significantly more common in patients who received fluoxetine, and CBT appeared to have a protective effect. Regardless of treatment assignment, nearly 75% of patients who did not meet response criteria at 12 weeks did so by 36 weeks, and responses tended to be maintained. Patterns were similar for remission. 4 Stage IV of the TADS was a 1-year naturalistic follow-up during which patients received only community mental health treatments (i.e., no study treatment). A total of 215 patients completed at least 1 stage IV assessment. The benefits of acute and continuation treatment persisted during follow-up. According to Clinical Global Impression Ratings, 82% of TADS patients were "minimally impaired" at 36 weeks. In contrast to the deterioration usually seen after discontinuing short-term medication, during TADS follow-up 13% of patients deteriorated to mildly-to-extremely impaired with no significant differences between the treatment groups. Discussion: "The central findings from the TADS are as follows: 1) combined treatment meaningfully accelerates recovery from depression relative to CBT and fluoxetine, 2) longerterm treatment results in improved outcomes relative to short-term treatment, 3) longer-term treatment may decrease the chances of relapse or recurrence when treatment is discontinued, C&A PSYCHIATRY ALERTS / September
4 and 4) adding CBT to fluoxetine minimizes persistent suicidal ideation and treatment-emergent suicidal events associated with medication monotherapy." Limitations include incomplete stage 4 data and no comparator treatment groups. 1 Treatment for Adolescents With Depression Study (TADS) Team: The treatment for adolescents with depression study (TADS): outcomes over 1 year of naturalistic follow-up. American Journal of Psychiatry. Published online September 1, 2009 at doi /appi.ajp From Duke University Medical Center, Durham, N.C.; and other institutions. Funded by the NIMH. Several study authors have disclosed commercial relationships that might pose conflicts of interest. 2 Treatment for Adolescents With Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004;292 (August 18): See Child & Adolescent Psychiatry Alerts 2004;6 (October): TADS Team: The treatment for adolescents with depression study (TADS): long-term effectiveness and safety outcomes. Archives of General Psychiatry 2007;64 (October): See Child & Adolescent Psychiatry Alerts 2007;9 (November): Rohde P, et al: Achievement and maintenance of sustained response during the treatment for adolescents with depression study continuation and maintenance therapy. Archives of General Psychiatry 2008;65 (April): See Child & Adolescent Psychiatry Alerts 2008;10 (May): CYP Genotype Affects Treatment Outcome A retrospective study found that increased cytochrome P450 (CYP) metabolizing ability decreased both psychotropic efficacy and adverse effects in a group of hospitalized children. This finding adds to the suggestion that genotype can play an important role in individualizing and optimizing psychotropic drug therapy. Background: Polymorphic genes associated with 2 cytochrome enzymes, CYP2D6 and CYP2C19, underlie some of the variability in patients' response to psychotropic medications metabolized via the CYP pathway. The present study examined the effects of genotype on the antiaggression efficacy of psychotropics and on drug tolerability. Methods: A cohort of 279 consecutively hospitalized children and adolescents who underwent genotyping as part of their routine care were included in the study. Based on their genotype, patients were categorized into 4 groups: combined poor metabolizer phenotype; combined intermediate metabolizer phenotype; combined extensive metabolizer phenotype; combined ultrarapid metabolizer phenotype. Patients had a median age of 13 years (range, 3 18 years) and were treated with a variety of drugs metabolized via the CYP pathway, including commonly used antipsychotics, antidepressants, and stimulants. Most were taking 1 (36%) or 2 (29%) psychotropic drugs. The primary outcome measure, the Behavioral Intervention Score, was based on the number of interventions for disruptive or aggressive behavior, such as time outs or physical restraints. Results: Behavioral Intervention Scores were lowest, indicating greatest treatment efficacy, in poor metabolizers, who represented 20% of the total. Scores were higher in the 22% of patients with the intermediate genotype, still higher in the 52% who were extensive metabolizers for both enzymes, and highest in the 6% of patients with the highest metabolizing ability. A secondary analysis showed that the CYP2D6 phenotype was predictive of treatment response, while the CYP2C19 phenotype was not. Adverse drug effects followed a similar but inverted pattern. Poor metabolizers experienced the most side effects (mean, 1.44) and the strongest metabolizers the fewest (mean, 0.75). Prows C, Nick T, Saldana S, Pathak S, et al: Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric patients. Journal of Child and Adolescent Psychopharmacology 2009;19 (August): From Cincinnati Children's Hospital Medical Center, Ohio; and other institutions. Funded by the NIH; and other sources. Several study authors disclosed commercial relationships that could pose conflicts of interest. 52 C&A PSYCHIATRY ALERTS / September 2009
5 Pediatricians' Treatment of ADHD Improving A survey of American Academy of Pediatrics (AAP) fellows shows the educational materials and treatment guidelines issued in 2000 and 2001 have resulted in improved quality of care. Background: Following a 1999 survey of current practice, the AAP launched a widespread educational campaign on the assessment and treatment of ADHD by pediatricians. The educational tools included a practice guideline, continuing education materials, and parent/patient handouts. A follow-up survey was mailed 6 years later to evaluate changes in practice after the campaign. Methods: Surveys were mailed in 1999 and 2005 to randomly selected AAP pediatricians involved in patient care. The later survey included questions and language from the initial survey as well as additional queries about the educational campaign, and both asked for responses regarding patients aged 6 12 years. Individual responses on evaluable surveys (452 and 551, respectively) were compared. Results: A total of 77% of the 2005 respondents reported familiarity with the AAP guidelines and 33 55% reported familiarity with other components of the educational package. According to the 2005 survey, pediatricians were more likely than in earlier years to use formal diagnostic criteria and standardized parent and teacher rating scales than narrative reports in the initial evaluation of ADHD. In both survey years nearly all pediatricians reported assessing for comorbidity, but in the later period, the assessments appear to have been more structured. Regardless of the survey year, more than 90% of pediatricians who treated children with ADHD reported using pharmacotherapy, most often methylphenidate (Ritalin), at least sometimes. In 2005, rather than refer to a subspecialist, pediatrician prescribers were more likely to try a different agent or add a second medication (when comorbid disorders were absent) if response was inadequate. Classroom modification and parent training were often recommended in both survey years; recommendation of alternative therapies decreased over time. After the educational campaign, more survey respondents felt adequately trained to evaluate and treat patients with simple ADHD, however at both time points a large percentage (60 63%) were uncertain about their abilities. Discussion: These results suggest that practice patterns in the treatment of ADHD by pediatricians have improved and are now more in line with treatment guidelines. This could improve outcomes for a substantial number of patients, as half of all pediatricians surveyed in 2005 reported treating simple ADHD themselves. Wolraich M, Bard D, Stein M, Rushton J, et al: Pediatricians attitudes and practices on ADHD before and after development of ADHD pediatric practice guidelines. Journal of Attention Disorders. Published online August 25, 2009 at doi / From the University of Oklahoma Health Sciences Center, Oklahoma City; and other institutions. Funded by the DHHS; and other sources. The authors did not include disclosure of potential conflicts of interest. Evidence-Based Psychopharmacology The American Academy of Child and Adolescent Psychiatry (AACAP) has released a practice parameter on the use of psychotropic medications in children and adolescents. The purpose is to promote the best practice principles of safe and appropriate psychotropic medication use for pediatric psychiatric disorders. Multiple steps are involved in the safe use of psychotropic medications. The first is to complete a thorough psychiatric evaluation. This should include interviews with both the patient and their parents or caregivers and is aimed at identifying symptoms and psychosocial factors that C&A PSYCHIATRY ALERTS / September
6 may bear upon a medication trial. Obtaining a medical history and ordering appropriate targeted medical testing (e.g., height and weight for stimulants, lipid profiles for antipsychotics) are also critical before initiating pharmacotherapy. Communication with all professionals involved in the child s care (e.g., teachers, pediatricians) will enhance the ability to provide optimal therapy. Prescribers should next develop a comprehensive treatment plan based on the best available evidence and educate both the patients and caregivers about the disorder and the suggested treatments. The plan should include both pharmacological and psychosocial interventions when appropriate and should detail acute treatment goals, starting dosages, scheduled increases, and methods for monitoring improvement and adverse effects. Maintenance and discontinuation phases as well as a follow-up monitoring plan should also be mapped and discussed with the patient and caregivers. Caution must be exercised when there are barriers to appropriate monitoring that can lead to inappropriate medication use. Informed consent/ assent from patients and caregivers must be obtained before starting or changing medications and should be documented in the medical record. When pharmacotherapy is the agreed upon course of action, dosages and duration of treatment should be outlined at initiation. If adequate improvement is not evident in a prespecified time frame, the patient should be reevaluated to ensure the initial diagnostic assessment was accurate and to identify possible nonadherence and/or psychosocial impediments to effective pharmacotherapy. Although there is little empirical evidence to support combination medication strategies, some may offer advantages over monotherapy or address emergent adverse effects. The same procedures as initial pharmacotherapy should be followed when adding an additional medication. Information on starting medications in children and adolescents is abundant, but less is known about optimal treatment durations and discontinuation strategies. Discontinuing medication also requires a specific plan that must be fully disclosed to the patient and caregivers. This plan includes not only tapering strategies, but also schedules of follow-up, and education regarding withdrawal and rebound symptoms as well as warning signs of possible recurrence. The AACAP does not advocate restricting pediatric access to psychopharmacological treatment. Rather, they strive to ensure prescribers are able to provide high-quality assessment and planning and prescribing practices that will enhance patient outcomes. Specific treatment advice for individual disorders is available in the practice parameter for each disorder, which are available at Walkup J, et al for the Work Group on Quality Issues: Practice parameter on the use of psychotropic medication in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2009;48 (September): From the American Academy of Child and Adolescent Psychiatry. The primary author and several members of the workgroup have disclosed commercial relationships that might pose conflicts of interest. Correction: In the August 2009 issue, in the story titled, "Autism: Genetic Research," on page 48 the reference should read: Geschwind D: Advances in autism. Annual Review of Medicine 2009;60: From the Department of Neurology, Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles. The author is a volunteer on the Autism Speaks Scientific Advisory Council. Contributing Editor: Bennett Silver, MD, Kate Casano, MSHyg Consulting Editor: Theodore A. Petti, MD, UMDNJ Robert Wood Johnson Medical School Executive Editor: Michael J. Powers Associate Editor: Trish Elliott Assistant Editors: Mandie Stahl, Krista Strobel Off-Label Drug Use Statement: Some drugs discussed for specific indications in Child & Adolescent Psychiatry Alerts articles may not be approved for labeling and advertising for those indications by the United States Food and Drug Administration. 54 C&A PSYCHIATRY ALERTS / September 2009
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care Illinois Department of Children and Family Services Introduction With few exceptions, children and adolescents in
More informationNew Monthly CME... Visit for details.
ADHD: Time-Management Deficits...23 CHILD & ADOLESCENT PSYCHIATRY ALERTS Antidepressants in Anxiety...19 Irritability and Suicide Risk...21 OCD Comorbidity...22 Reference Guide...24 Suicide Predictors
More informationPSYCHIATRY ALERTS. Conduct Disorder in Girls. Basal Ganglia Morphology and Stimulants in ADHD
Basal Ganglia Morphology in ADHD...37 Conduct Disorder in Girls...37 CHILD& ADOLESCENT PSYCHIATRY ALERTS Histamine, Food Additives, and ADHD...38 Lithium Pharmacokinetics...40 Migraine and Mental Illness...40
More informationPSYCHIATRY ALERTS CHILD& ADOLESCENT. Cyber Bullying and Depression
ADHD Resources...17 CHILD& ADOLESCENT PSYCHIATRY ALERTS Benefits of Treating Maternal Depression...14 DBS Complications...16 Depression and Cyber Bullying...13 Depression: Recovery and Recurrence...15
More informationPSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE
PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE Introduction and General Principles April 2017 Adapted for New Mexico from with permission from the Texas Department
More informationADHD, Stimulants, and Sexual Maturation...64 CBT vs. Sertraline in OCD...63 CHILD & ADOLESCENT. NEW... Online CME Now Available! Call us for details.
ADHD, Stimulants, and Sexual Maturation...64 CBT vs. Sertraline in OCD...63 CHILD & ADOLESCENT PSYCHIATRY ALERTS Volume XVI / November 2014 / Number 11 Dialectical Behavior Therapy for Self-Harm...61 Generic
More informationNew Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services
New Jersey Department of Children and Families Policy Manual Manual: CP&P Child Protection and Permanency Effective Volume: V Health Date: Chapter: A Health Services 1-11-2017 Subchapter: 1 Health Services
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationChange Coming... See back page for details.
ADHD and Diabetes...31 CHILD & ADOLESCENT PSYCHIATRY ALERTS ADHD: Nonpharmacological Treatments...34 Callous Unemotional Traits: Family Effects...32 Important Notice...36 Intensive Treatment After Discharge...35
More informationPSYCHIATRY ALERTS CHILD& ADOLESCENT. Severe Mood Dysregulation or Bipolar Disorder?
Aripiprazole Augmentation in OCD...69 CHILD& ADOLESCENT PSYCHIATRY ALERTS INDEX...70 Methylphenidate-Associated Priapism...68 Reference Guide...70 Severe Mood Dysregulation...67 Volume XII / December 2010
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationChange Coming... See back page for details.
Amphetamine Extended-Release Suspension...38 CHILD & ADOLESCENT PSYCHIATRY ALERTS Antipsychotics: Early Metabolic Effects...41 DBT for Suicidal Behavior...39 Important Reminder...42 Reference Guide...42
More informationImportant Reminder... Delivery of Child & Adolescent Psychiatry Alerts is now 100% electronic.
ADHD Medication Comparison...53 CHILD & ADOLESCENT PSYCHIATRY ALERTS Adjunctive tdcs for Anorexia Nervosa...52 Asenapine in Bipolar Disorder...50 Depression Screening Tools...52 Enhanced CBT for Panic
More informationNEW... Online CME Now Available! Call us for details.
Biomarker for Depression Polarity...53 CHILD & ADOLESCENT PSYCHIATRY ALERTS Duloxetine Pharmacokinetics...53 Non-Suicidal Self-Injury...49 Parent Goals for ADHD Treatment...52 Reference Guide...54 Stimulants
More informationPSYCHIATRY ALERTS. Optimizing Stimulants Improved Aggression
D-Cycloserine Enhances CBT...52 Pineal Tumor and Psychosis...53 CHILD& ADOLESCENT PSYCHIATRY ALERTS Predicting Atomoxetine Response...50 Reference Guide...54 Self-Perception in ADHD...50 Stimulants and
More information5/12/11. Educational Objectives. Goals
Educational Objectives Learn: steps for initial depression screening and management in primary care when to refer to mental health providers tools for providers and patients principles of collaborative
More informationTITLE: Practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder.
Brief Summary TITLE: Practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder. SOURCE(S): Practice parameters for the assessment and treatment
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationPediatric Primary Care Mental Health Specialist Certification Exam. Detailed Content Outline
Pediatric Primary Care Mental Health Specialist Certification Exam Detailed Content Outline Description of the Specialty The Pediatric Primary Care Mental Health Specialist (PMHS) builds upon the Advanced
More informationAbilify: Generic Approval...25 DBT in Adolescent Bipolar Disorder...26 CHILD & ADOLESCENT
Abilify: Generic Approval...25 DBT in Adolescent Bipolar Disorder...26 CHILD & ADOLESCENT PSYCHIATRY ALERTS Volume XVII / May 2015 / Number 5 Duloxetine for Generalized Anxiety Disorder...28 ECT in Adolescents
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationPathway to Care. Rationale. Organization of the Pathway. Education about the Suicide Safe Care Pathway
Pathway to Care Goal 7: Individuals assessed to be at risk will receive care in accordance with the Suicide Safe Care Pathway. Agencies will use quality management tools to monitor adherence to the Suicide
More informationImportant Notice Change Coming... See back page for details.
Anxiety in Emerging Adulthood...27 CHILD & ADOLESCENT PSYCHIATRY ALERTS Aripiprazole vs Quetiapine: QT Effects...29 Asenapine: Pediatric Use...28 Important Notice...30 Marijuana Legalization and Mental
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationPSYCHIATRY ALERTS CHILD& ADOLESCENT. Prazosin for Pediatric PTSD. Atypical Antipsychotics and Diabetes Risk
Antidepressants, Stimulants, and Mania...68 CHILD& ADOLESCENT PSYCHIATRY ALERTS Diabetes Risk with Antipsychotics...67 INDEX...70 Prazosin for PTSD...67 Reference Guide...70 Soda Linked with Violent Behavior...69
More informationNeed CME? Go to alertpubs.com and click on the Continuing Education tab.
Aripiprazole in Resistant OCD...63 CHILD & ADOLESCENT PSYCHIATRY ALERTS Atypicals plus Stimulants...64 Depression Prevention...62 Generic Concerta Equivalence...61 Methylphenidate/Acetaminophen Interaction...64
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationConsolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults
FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca
More informationCurricular Components for General Pediatrics EPA EPA Title Assess and manage patients with common behavior/mental health problems
Curricular Components for General Pediatrics EPA 9 1. EPA Title Assess and manage patients with common behavior/mental health problems 2. Description of the activity Mental health and behavioral issues
More informationQuestions about Self-Assessment CME? We have the answers! See back page for details.
Antidepressant Switching or Augmentation...61 PSYCHIATRY DRUG ALERTS Volume XXXI / August 2017 / Number 8 Fluoxetine for Hypochondriasis...58 Fluvoxamine with Clozapine...57 Ketamine Recommendations...59
More informationTALKING TO PATIENTS AND FAMILIES ABOUT MEDICATIONS: IMPROVING QUALITY OF CARE AND REDUCING PROFESSIONAL LIABILITY RISK WHEN PRESCRIBING FOR CHILDREN
A benefit of participation in TALKING TO PATIENTS AND FAMILIES ABOUT MEDICATIONS: IMPROVING QUALITY OF CARE AND REDUCING PROFESSIONAL LIABILITY RISK WHEN PRESCRIBING FOR CHILDREN Introduction This article
More informationPsychotropic Medication
FOM 802-1 1 of 10 OVERVIEW The use of psychotropic medication as part of a child s comprehensive mental health treatment plan may be beneficial and should include consideration of all alternative interventions.
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationChoosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care
Choosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care JASON BEAMAN D.O., M.S., FAPA ASSISTANT CLINICAL PROFESSOR CHAIR, DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES OKLAHOMA STATE
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationAllegany Rehabilitation Associates Personalized Recovery Oriented Services. Diagnoses: Bipolar 1 or 2 Disorder, Schizoaffective Disorder
Title of Service: Coping with Bipolar Disorder Total Number of Sessions: 13 Duration of each session: 45 Minutes PROS Service: CRS Wellness Self Management Target population: Diagnoses: Bipolar 1 or 2
More informationAdjunctive VNS in Depression...51 PSYCHIATRY. Important Reminder... Delivery of Psychiatry Alerts NOS is now 100% electronic.
Adjunctive V in Depression...51 PSYCHIATRY ALERTS NOS Biological Aging and Depression...52 Reference Guide...54 Self-Injury: Online Self-Help...51 Smartphone Apps for Mental Health...53 Substance Abuse
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationATTENTION DEFICIT DISORDER; AEROMEDICAL CONSIDERATIONS
ATTENTION DEFICIT DISORDER; AEROMEDICAL CONSIDERATIONS David Bryman, D.O Senior International Aviation Medical Examiner FAA, EASA, Australia, New Zealand, Canada drbryman@gmail.com Disclosure Information
More informationNew Monthly CME... Visit for details.
Antidepressants: Optimal Duration...9 CHILD & ADOLESCENT PSYCHIATRY ALERTS Multisystemic Therapy for Antisocial Behavior...10 Olanzapine for Restrictive Eating Disorder...7 Reference Guide...12 Tourette
More informationAdolescent depression
Diagnostic skills can differentiate 40 VOL. 1, NO. 7 / JULY 2002 teen angst from psychopathology Ann Wagner, PhD Chief, Autism and Pervasive Developmental Disorders Intervention Research Program Benedetto
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationDisclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013
A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationSECTION 1. Children and Adolescents with Depressive Disorder: Summary of Findings. from the Literature and Clinical Consultation in Ontario
SECTION 1 Children and Adolescents with Depressive Disorder: Summary of Findings from the Literature and Clinical Consultation in Ontario Children's Mental Health Ontario Children and Adolescents with
More informationTreating Disruptive Behavior Disorders in Children and Teens. A Review of the Research for Parents and Caregivers
Treating Disruptive Behavior Disorders in Children and Teens A Review of the Research for Parents and Caregivers e Is This Information Right for Me? This information is for you if: A health care professional*
More informationDisruptive Mood Dysregulation Disorder
Walden University ScholarWorks School of Counseling Publications College of Social and Behavioral Sciences 2015 Disruptive Mood Dysregulation Disorder Brandy L. Gilea Walden University Rachel M. O Neill
More informationAttention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D.
ADHD in Preschool Children Preschool ADHD: When Should We Diagnose it & How Should We Treat it? Professor of Pediatrics Diagnosis of ADHD in Preschool Children: Impact of DSM-IV Is Preschool ADHD Associated
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationTreatment for Bipolar Disorder
A Resource for Consumers Treatment for Living with bipolar disorder can be a challenge. With the help of your treatment team, family, friends, and by sticking to a treatment plan, you may be able to better
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationADHD in the Preschool Aged Child
ADHD in the Preschool Aged Child (PATS) 11/2/2013 Stephen Meister MD, MHA, FAAP The Edmund N Ervin Pediatric Center (PATS) National Institute of Mental Health study First papers published in 2006 after
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationApplication of Psychotropic Drugs in Primary Care
Psychotropic Drugs Application of Psychotropic Drugs in Primary Care JMAJ 47(6): 253 258, 2004 Naoshi HORIKAWA Professor, Department of Psychiatry, Tokyo Women s Medical University Abstract: The incidence
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationMCPAP Clinical Conversations:
MCPAP Clinical Conversations: After the screen: A Practical Approach to Mental Health Assessment in the Pediatric Primary Care Setting Barry Sarvet, MD Professor and Chair of Psychiatry, UMMS-Baystate
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationDepression: Assessment and Treatment For Older Adults
Tool on Depression: Assessment and Treatment For Older Adults Based on: National Guidelines for Seniors Mental Health: the Assessment and Treatment of Depression Available on line: www.ccsmh.ca www.nicenet.ca
More informationUNDERSTANDING BIPOLAR DISORDER Young Adult: Get the Facts
UNDERSTANDING BIPOLAR DISORDER Young Adult: Get the Facts What does it mean when a health care professional says bipolar disorder? At first, it was quite scary Hearing a health care professional say you
More informationMODEL PSYCHOPHARMACOLOGY CURRICULUM
Third Edition MODEL PSYCHOPHARMACOLOGY CURRICULUM For Psychiatric Residency Programs, Training Directors and Teachers of Psychopharmacology VOLUME I By A Committee of the American Society of Clinical Psychopharmacology
More informationAntidepressants for treatment of depression.
JR3 340 1 of 9 PSYCHOTROPIC MEDICATIONS PURPOSE The use of psychotropic medication as part of a youth's comprehensive mental health treatment plan may be beneficial. The administration of psychotropic
More informationNew Research in Depression and Anxiety
New Research in Depression and Anxiety Robert Glassman Introduction Depression and anxiety are some of the most common disorders of childhood and adolescence. New research in these areas explores important
More informationEARLY ONSET SCHIZOPHRENIA
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington
More informationSummary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate)
Part VI: Summary of the risk management plan Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) This is a summary of the risk management plan (RMP) for
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationAttention Deficit Hyperactivity Disorder
AMS-MOH CLINICAL PRACTICE GUIDELINES 1/2014 Attention Deficit Hyperactivity Disorder Academy of Medicine, Singapore College of Paediatrics and Child Health, Singapore College of Family Physicians Singapore
More informationMending the Mind: treatment of the severely mentally ill
Mending the Mind: treatment of the severely mentally ill First, the bad news Mental Illness Prevalence: putting things in perspective --More than 54 million Americans have a mental disorder in any given
More informationGOALS FOR THE PSCYHIATRY CLERKSHIP
GOALS FOR THE PSCYHIATRY CLERKSHIP GOALS - The aim of the core psychiatry clerkship is to expose students to patients with mental illness and to prepare them to provide psychiatric care at a basic level.
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More information8. DEPRESSION 1. Eve A. Kerr, M.D., M.P.H. and Kenneth A. Clark, M.D., M.P.H.
8. DEPRESSION 1 Eve A. Kerr, M.D., M.P.H. and Kenneth A. Clark, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression: the AHCPR Clinical Practice Guideline in
More informationEating Disorders in Youth
Eating Disorders in Youth Evaluating and Treating in the Medical Home February 27, 2017 Rebecca Marshall, MD, MPH Outline Anorexia Nervosa Bulimia Nervosa Binge Eating Disorder Avoidant Restrictive Food
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationNow Available... ABPN-Approved Self-Assessment CME. Visit for details.
Brain Stimulation for Depression...56 CHILD & ADOLESCENT PSYCHIATRY ALERTS Cognitive Psychological Treatment for Tics...58 Parental Depression: Impact on Offspring...57 Reference Guide...60 Stimulants
More informationSuicide Risk Management Clinical Strategies
Suicide Risk Management Clinical Strategies March 12, 2015 Steven Vannoy, PhD, MPH steven.vannoy@umb.edu Department of Counseling and School Psychology University of Massachusetts Boston Review: What Explains
More informationOptimistic News and Practical Tools. The Role of Primary Care in Screening and Managing Teen Depression
Optimistic News and Practical Tools The Role of Primary Care in Screening and Managing Teen Depression Meg Durbin, MD Palo Alto Medical Foundation DurbinM@pamf.org Educational Objectives Learn: steps for
More informationTreatment of Major Depression In Adolescents. Ian M Goodyer OBE MD FRCPsych FMedSci University of Cambridge
Treatment of Major Depression In Adolescents Ian M Goodyer OBE MD FRCPsych FMedSci University of Cambridge DSM: Unipolar Major Depression Irritability/anger Depressed mood Anhedonia Cognitive disturbance
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder
Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM
Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More informationSUBSTANCE USE/ABUSE CODING FACT SHEET FOR PRIMARY CARE CLINICIANS
SUBSTANCE USE/ABUSE CODING FACT SHEET FOR PRIMARY CARE CLINICIANS Current Procedural Terminology (CPT ) (Procedure) Codes Initial assessment usually involves a lot of time determining the differential
More information2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an
Quality ID #370 (NQF 0710): Depression Remission at Twelve Months National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health
More informationMCPAP Clinical Conversations: Attention Deficit/Hyperactivity Disorder (ADHD) Update: Rollout of New MCPAP ADHD Algorithm
MCPAP Clinical Conversations: Attention Deficit/Hyperactivity Disorder (ADHD) Update: Rollout of New MCPAP ADHD Algorithm Jefferson Prince, MD Co-Medical Director Eastern MCPAP Teams May22, 2018 1 Overview
More informationPediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form
Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form Please fax form to 617.673.0988 or mail to Tufts Health Plan, 705 Mount Auburn Street, Watertown, MA 02472, Attn:
More informationCare Team Training. Key Components of Collaborative Care. Collaborative Team Approach 4/21/2014 PCP. Core Program. New Roles. Psychiatric Consultant
Team Training Key Components of Collaborative Collaborative Team Approach Patient PCP Manager New Roles Core Program Psychiatric Consultant Behavioral Health Clinicians Additional Clinic Resources Substance,
More informationQUALITY ASSESSMENT (QA) MANUAL
QUALITY ASSESSMENT (QA) MANUAL RFP-NIH-NIMH 98-DS-0008 Treatment for Adolescents with Depression Study (TADS) Principal Investigator: John S. March, MD, MPH. Duke University Medical Center with Duke Clinical
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationNow Available... ABPN-Approved Self-Assessment CME. (See last page.)
ADHD: Neural and Genetic Correlates...37 CHILD & ADOLESCENT PSYCHIATRY ALERTS Antidepressants: Relative Efficacy...40 Antipsychotics: Cardiac Safety...39 Methylphenidate: Cardiac Safety...38 Puberty and
More information10 INDEX Acknowledgements, i
INDEX 10 INDEX Acknowledgements, i Acute Care, Admissions to, 3.83 Discharge Planning, 3.86 Involuntary Admission Criteria, 3.84 List of Designated Provincial and Regional Mental Health Facilities, 3.83
More informationDisclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017
Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017
More informationLife Care Plan. Kobe Williams. Projected Evaluations. Per Unit. Per Year
Projected Evaluations Rehabilitation Long-Term Needs Assessment 4 8/16/01 21 2018 3 X Only Assess Handicapping Conditions 1 X Already accomplished as of 4/19/01 evaluation; reevaluations recommended at
More informationCurbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care
Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care Appendices Appendix A Psych Meds Data Indicators by State The data elements being collected by the
More information